ZRP
Tuca Zbarcea & Asociatii

IP Right Enforcement in the EU: CJEU Reduces Claimant’s Liability Risk when Seeking Preliminary Injunctions

18 Noiembrie 2019   |   Schoenherr

The result of the decision, however, raises the question of whether national laws comply with the requirements of the Enforcement Directive as interpreted by the CJEU in the Bayer Pharma decision.

 
 
The Court of Justice of the EU (CJEU) recently dealt with "appropriate compensation" due in cases where a preliminary injunction based on IP rights was lifted or not rectified in subsequent main proceedings.

Compensation for unjustified preliminary measures under EU law

Case C-688/17, Bayer Pharma, concerned questions for a preliminary ruling brought by a Hungarian court in patent infringement proceedings. In these proceedings the court issued preliminary injunctions, which were finally revoked due to the invalidity of the patent. The successful defendants therefore subsequently claimed compensation for losses incurred due to the apparently unjustified preliminary injunction.  

In its decision, the CJEU states that "appropriate" (a term used in Article 9(7) of the EU Enforcement Directive aimed at facilitating enforcement of IP rights) as a concept of EU law must be given an independent and uniform interpretation in all EU Member States and that an assessment of whether damages are "appropriate" must take into account the overall circumstances of each case. The courts are therefore not automatically and not in every case obliged to grant compensation for damages if a preliminary injunction is subsequently not rectified, but "only in the case of an unjustified application". The CJEU links the answer to the question of whether an application was "unjustified" not only to the objective circumstance that the preliminary injunction could not be rectified in the subsequent main proceedings. It even requires on the subjective side that the application was filed "abusively". Otherwise, the IP right holders could be deterred from applying for preliminary measures at all, which would contradict the Enforcement Directive's objective of ensuring a high, equivalent and homogeneous level of protection for intellectual property (including industrial property rights).


Impact on national laws

The result of the decision, however, raises the question of whether national laws comply with the requirements of the Enforcement Directive as interpreted by the CJEU in the Bayer Pharma decision.

For example, the national legislation in Hungary (as enshrined by the decision of the CJEU) permits the court to take due account of the negligence or fault of both the party applying for the preliminary injunction and the defendant. Although the provisions of the old Civil Code (Act IV of 1959) assessed by the CJEU have been replaced in the meantime by the new Civil Code (Act V of 2013), the substance of the new rules remains unchanged. The injured party is obliged to act as would generally be expected in the circumstances in question to avoid or to mitigate the loss. The injured party will not be compensated for loss resulting from its failure to comply with this obligation. These provisions are a double-edged sword resulting in the conduct of both parties being assessed on a case-by-case basis, i.e. whether the applicant applied for the preliminary injunction abusively, and whether the party suffering loss from such an injunction indeed did what was expected to avoid the loss (e.g. by not marketing the product before the conclusion of the patent invalidity proceedings). In the CJEU's view this national legislation should be in line with the objectives of the Enforcement Directive.

On the other hand, Section 394 of the Austrian Enforcement Act (Exekutionsordnung) foresees strict liability for damages caused by unrectified preliminary injunctions regardless of negligence or fault, which no longer seems to be in line with the findings of the CJEU.

The CJEU thus brought some clarity to the EU-wide interpretation of the Enforcement Directive, certainly decreasing the risk for IP owners to enforce their rights via preliminary measures in the EU. However, important questions still need to be resolved by the national courts (or even the CJEU in subsequent proceedings). Particularly which circumstances would qualify as "abusive" pursuant to the CJEU but also the applicability in proceedings other than those directly dealing with the enforcement of registered IP rights (i.e. unfair competition claims, trade secret protection, etc.) seems to provide some room for future discussion.
 
 

PNSA

 
 

ARTICOLE PE ACEEASI TEMA

ARTICOLE DE ACELASI AUTOR


 

Ascunde Reclama
 
 

POSTEAZA UN COMENTARIU


Nume *
Email (nu va fi publicat) *
Comentariu *
Cod de securitate*







* campuri obligatorii


Articol 4254 / 4430
 

Ascunde Reclama
 
BREAKING NEWS
ESENTIAL
MergerMarket League Tables - Full Year 2024 | Piața de M&A a cunoscut o redresare prudentă anul trecut și a înregistrat o creștere de 8 % la nivel global. CMS, printre primele în clasamentul global și în Europa. Schoenherr și Wolf Theiss, număr mare de tranzacții asistate în Europa Centrală și de Est
Wolf Theiss a asistat fondatorii Embryos Fertility Clinic cu privire la vânzarea pachetului majoritar de părţi sociale către Integral Capital Group, alături de care a stat RTPR | Ce avocați au fost în cele două echipe
Practica de protecție a datelor este o componentă strategică a firmei Wolf Theiss, existând o cerere crescătoare în acest domeniu. Viitorul acestei arii este unul promițător, având în vedere majorarea volumului de date prelucrate și evoluțiile tehnologice rapide, spun avocații | Flavius Florea - Counsel: „Un aspect cheie este legat de avansul tehnologic, cum ar fi utilizarea tot mai frecventă a inteligenței artificiale și provocările aferente respectării principiilor GDPR”
Stratulat Albulescu o recrutează pe Andreea Șerban de la Reff & Asociații, pe poziția de Partener
Trei ofertanți intră în a doua rundă a vânzării Amethyst Healthcare, lanț paneuropean de radioterapie cu șase clinici în România. Goldman Sachs supraveghează tranzacția
Noi promovări în echipa RTPR | Andreea Nedeloiu devine Counsel, alți cinci avocați au terminat stagiatura și vin pe poziția de Associate
Promovări la Voicu & Asociații | Roxana Neguțu devine Senior Partner, noi poziții ocupate în cadrul Firmei
Filip & Company asistă eMAG şi HeyBlu în achiziția a 100% din acțiunile Orange Money IFN SA. Echipa, coordonată de Alina Stancu Bîrsan (partener) și Rebecca Marina (counsel)
Academia Română, reprezentată de Popescu & Asociații, obține o victorie semnificativă într-un proiect complex de retrocedare | Echipa coordonată de Octavian POPESCU (Managing Partner), Andreea MIHALACHE (Partner) și Ana Maria BULEA-CIURARU (Associate) stabilește un precedent important în protejarea bunurilor de importanță națională
O nouă echipă de coordonare la Filip & Company | Cristina Filip și Alexandru Bîrsan, co-Managing Partners, au un mandat de 4 ani. Mai mulți parteneri devin manageri sau co-manageri ai departamentelor firmei
VIDEO | Dicționar de arbitraj: Intervenția instanței în arbitraj (Powered by ZRVP)
Mușat & Asociații promovează șapte avocați în ariile fuziuni și achiziții, litigii și arbitraj, drept bancar și financiar, piețe de capital și achiziții publice
 
Citeste pe SeeNews Digital Network
  • BizBanker

  • BizLeader

      in curand...
  • SeeNews

    in curand...